1mg elsunersen + 0.5mg elsunersen
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Epileptic Encephalopathy
Conditions
Epileptic Encephalopathy, SCN2A Encephalopathy
Trial Timeline
Aug 13, 2025 → Dec 1, 2028
NCT ID
NCT07019922About 1mg elsunersen + 0.5mg elsunersen
1mg elsunersen + 0.5mg elsunersen is a phase 3 stage product being developed by Praxis Precision Medicines for Epileptic Encephalopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07019922. Target conditions include Epileptic Encephalopathy, SCN2A Encephalopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07019922 | Phase 3 | Recruiting |
Competing Products
14 competing products in Epileptic Encephalopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Perampanel Oral Suspension + Perampanel Tablet | Eisai | Phase 2 | 52 |
| Lorazepam | Pfizer | Phase 3 | 76 |
| Lorazepam | Pfizer | Pre-clinical | 22 |
| levetiracetam (add-on) | UCB | Phase 2 | 49 |
| ESES treated with clobazam | Lundbeck | Pre-clinical | 20 |
| NBI-921352 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-827104 | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-921352 | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-827104 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Phase 1 | 30 |
| 1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo | Praxis Precision Medicines | Phase 3 | 74 |
| SAGE-547 | Supernus Pharmaceuticals | Pre-clinical | 18 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 3 | 72 |